In this study, these results demonstrated that KPs treatment can regulate immune functions to decrease inflammatory cytokine release, CD4+ T cell proliferation and Th1/Th17 cytokine production, to suppress splenic DC maturation and to alleviate all the symptoms of collagen type II-induced arthritis in the mouse model. This evidence concerns the gene CD4 and arthritic joint disease.